ArticleCurrent medical science2026
Efficacy and Safety of Switching from Entecavir to Tenofovir Alafenamide for Chronic Hepatitis B Patients with Low-Level Viremia.
Article in Current medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveClinical data on the efficacy and safety of tenofovir alafenamide fumarate (TAF) in chronic hepatitis B (CHB) patients with suboptimal response to entecavir (ETV) are limited. This study was designed to investigate the efficacy and safety of switching to TAF in CHB patients with low-level viremia (LLV).
methodsCHB patients with LLV who received ETV treatment for more than 52 weeks were divided into TAF group (n = 104) and ETV group (n = 395). Propensity score matching (PSM) was performed to adjust for baseline differences in age between the two groups. The outcomes included complete virological response (CVR) at weeks 12 and 24, normalization rates of aminotransferase (ALT) and aspartate aminotransferase (AST), and renal function and blood lipid levels.
resultsCompared with the ETV group, the TAF group had significantly higher rates of CVR at week 12 and week 24 in both the raw cohort and the PSM cohort (all P < 0.05). In the PSM cohort, the superiority of TAF over ETV in achieving CVR remained statistically significant at both time points (all P < 0.05). ALT and AST normalization rates were also significantly greater in the TAF group than in the ETV group at week 24 (all P < 0.05). No significant differences in creatinine (Cr) levels or estimated glomerular filtration rate (eGFR) were observed between week 24 and baseline in the raw cohort. No significant changes in blood lipid levels were detected in the TAF group at week 24 (all P > 0.05).
conclusionSwitching to TAF may be beneficial for patients with LLV after prolonged ETV therapy, as it is associated with a significantly higher rate of CVR. No lipid metabolism-related disorders were observed following the switch to TAF.
Indexed as
Identifiers
42709398What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.